Levodopa and the progression of Parkinson's disease.

Keywords

Levodopa, Medicine, Parkinsonism, Placebo, Carbidopa

References

• Levodopa-Induced NeurotoxicityStanley Fahn — 1997
• Is There a Rationale for Neuroprotection Against Dopamine Toxicity in Parkinson's Disease?Ari Barzilai, Eldad Melamed, Anat Shirvan — 2001
• Neuroleptic malignant syndrome in advanced Parkinson's diseaseManuel Seijo Martínez, M. Fontoira, G. Celester — 2001
• Recent Developments in Parkinson's DiseaseStanley Fahn, RL Elton, C. D. Marsden — 1986
• Is levodopa toxic to human substantia nigra?Ali H. Rajput, Mark Fenton, Sam Birdi — 1997
• Time course of nigrostriatal degeneration in parkinson's diseasePeter Riederer, St. Wuketich — 1976
• Reproducibility and Effect of Levodopa on Dopamine Transporter Function Measurements: A [18F]CFT PET StudyElina Nurmi, Jörgen Bergman, Olli Eskola — 2000
• Decreased single‐photon emission computed tomographic 123Iβ‐CIT striatal uptake correlates with symptom severity in parkinson's diseaseJohn Seibyl, K. L. Marchek, Donald M. Quinlan — 1995
• Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesionsMario Gustavo Murer, Gustavo Dziewczapolski, Liliana Menalled — 1998
• Levodopa: Is toxicity a myth?Yves Agid — 1998
• Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET studyAlan Whone, Ray L. Watts, A. Jon Stoessl — 2003
• Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanismsM. A. Mena, Marı́a José Casarejos, Ana Carazo — 2005
• Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's diseaseRobert A. Hauser, William C. Koller, Jean Hubble — 2000
• Preservation of the substanitia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four‐year periodNiall Quinn, David G. Parkes, I. Janota — 1986
• Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's diseaseRobert A. Hauser, Nicholas H. G. Holford — 2002
• The effect of deprenyl and levodopa on the progression of Parkinson's diseaseC. Warren Olanow, Robert A. Hauser, L. Gauguster — 1995
• ParkinsonismMargaret M. Hoehn, Melvin D. Yahr — 1967
• Is levodopa toxic?Stanley Fahn — 1996
• Neurotrophic Effects of l‐DOPA in Postnatal Midbrain Dopamine Neuron/Cortical Astrocyte CoculturesMaría A. Mena, Viviana Davila, David Sulzer — 1997
• A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal.Joseph H. Friedman — 1985

Cited by

• Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease.Mercedes Unzeta, Elisenda Sanz — 2011
• Treatment should not be initiated too soon in Parkinson's diseaseЕ В Рябова, Галина Анатольевна Шулугина — 2006
• Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.Arístides Jorge Viera González — 2007
• Assessment of Parkinson's disease with imaging.Olivier Mariez — 2007
• Behandlungs- und Versorgungsstrategien bei Alzheimer und verwandten Demenzen修 宮田, 貴子 黒田, 正一 原 — 2008
• Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.Thierry Ripoll, Jacques Vauclair — 2010
• Calcium‐permeable AMPA receptors are involved in the induction and expression of l‐DOPA‐induced dyskinesia in Parkinson’s diseaseJ Li, WK Li, KP Wat — 2010
• Levodopa: back to the futureJoe I. Mendoza — 2010
• Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson's diseaseJe G., Kyong Soo Park — 2011
• Bayesian Quantitative Disease–Drug–Trial Models for Parkinson’s Disease to Guide Early Drug Development潔 竹脇 — 2011
• The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson's DiseaseDaniel Grossman — 2011
• Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analysesStefan Leucht, Sandra Hierl, Werner Kissling — 2012
• How to treat Parkinson's disease in 2013.N. Pogna — 2013
• Effects of l-DOPA on striatal iodine-123-FP-CIT binding and behavioral parameters in the ratŽeljko Rapanić — 2013
• The Nature of Progression in Parkinson’s Disease: An Application of Non-Linear, Multivariate, Longitudinal Random Effects ModellingJoão Ricardo Carvalho de Souza — 2013
• Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s diseaseAníbal Sánchez Andrés — 2015
• Integrative Frequency Power of EEG Correlates with Progression of Mild Cognitive Impairment to Dementia in Parkinson’s Disease好治 井田 — 2016
• Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia.智 西村 — 2016
• Clinical characteristics of fatigued Parkinson’s patients and the response to dopaminergic treatmentPilar Porcel — 2016
• Minimal clinically important differences for the experiences of daily living parts of movement disorder society–sponsored unified Parkinson's disease rating scaleIsabel Pinedo Noriega — 2017

Related papers

• Carbidopa/levodopa and selegiline do not affect platelet mitochondrial function in early parkinsonismClifford W. Shults, Fatemeh Nasirian, David M. Ward — 1995
• Levodopa-Responsive Benign Tremulous ParkinsonismOsamu Kano, Shinichi Okonogi, Sayori Hanashiro — 2013
• Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months.T. S. Elizan — 1991
• Treatment of Parkinson's disease.Abraham Lieberman — 1993
• Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension.Kirsty Bhattacharya, Soraya Nouri, C. Warren Olanow — 2003
• Combination of selegiline and controlled release levodopa in the treatment of fluctuations of clinical disability in parkinsonian patientsC Chouza, Ruth Aljanati, A. Scaramelli — 1989
• Selegiline in de novo parkinsonian patients: The finnish studyVilho V. Myllylä, K. A. Sotaniemi, Jouni Vuorinen — 1993